Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

The scale of the Merck layoffs has not been revealed, but the company indicated that it would target roles in the ...

Merck (NYSE: MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst ...

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware Apr. 29, 2025 6:45 AM ET Merck & Co., Inc. (MRK) ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

Merck is seeking confirmation that Bayer is liable for talc claims that have been filed against both companies since 2014 when Bayer bought product lines from Merck in a $14 billion deal. The ...